Mark McDonnell
@Arch Venture Management, Llc
Latest period2024 - Q3ReportedManaged Assets$260.56MTotal holdings9
Assets growth rate-2.05%Assets growth rate (2-Q avg)114.67%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Arch Venture Management, Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 9 positions.
Assets under management
The assets under management (AUM) of Arch Venture Management, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 260.56M in assets, with a quarterly growth rate of -2.05% and a 2-quarter average growth rate of 114.67%. The portfolio is managed by Mark McDonnell, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
BEAMBeam Therapeutics Inc.
| 45.46% | $118.449M 4.835M shares@ $24.51 avg price | Decreased -11.17% |
RAPPRapport Therapeutics, Inc.
| 29.31% | $76.365M 3.729M shares@ $20.48 avg price | |
ERASErasca, Inc.
| 11.59% | $30.182M 11.056M shares@ $2.73 avg price | |
QTTBQ32 Bio Inc.
| 5.49% | $14.3M 320,482 shares@ $44.63 avg price | |
VERVVerve Therapeutics, Inc.
| 3.74% | $9.723M 2.009M shares@ $4.85 avg price | |
GOSSGossamer Bio, Inc.
| 3.05% | $7.946M 8.056M shares@ $0.99 avg price | |
OMICSingular Genomics Systems, Inc.
| 0.77% | $1.984M 126,630 shares@ $15.67 avg price | |
UBXUnity Biotechnology, Inc.
| 0.57% | $1.477M 1.005M shares@ $1.48 avg price | |
CEROCero Therapeutics Holdings, Inc.
| 0.06% | $134,753 1.444M shares@ $0.1 avg price |